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Background and Objectives: Desmoid tumors are soft‐tissue tumors originating from
myofibroblasts with a tendency to recur after surgery. High expression of
proliferation markers is associated with shortened progression‐free and/or overall
survival in many neoplasms, including soft‐tissue sarcomas. We investigated the
prognostic role of cyclin A and Ki67 in desmoid tumors by immunohistochemistry.
Methods: The study included 76 patients with desmoid tumor operated at Helsinki
University Hospital between 1987 and 2011. A tissue micro array (TMA) was
constructed and the TMA sections were immunostained with cyclin A and Ki67
antibodies. A computer‐assisted image analysis was performed.
Results: Cyclin A expression was evaluable in 74 and Ki67 in 70 patients. Cyclin A
immunopositivity varied from 0% to 9.9%, with a mean of 1.9%. Cyclin A expression
correlated significantly with Ki67. Cyclin A expression was associated with recurrence‐
free survival (HR 1.9, 95% CI = 1.1‐3.2, P = .02), as were positive margin (HR 6.0, 95% CI
= 1.6‐22.5, P = .008) and extremity location (HR 5.3, 95% CI = 1.7‐16.8, P =0.005). Ki67
immunopositivity varied from 0.33% to 13.8%, with a mean of 4.6%, but had no
significant prognostic impact (HR 1.1, P = .2).
Conclusions: Our study indicates that cyclin A may be a new prognostic biomarker in
surgically treated desmoid tumors.
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1 | INTRODUCTION
Neoplastic growth depends on the proliferation rate, the number of
quiescent cells, and apoptosis. The cellular proliferation marker cyclin
A2 activates the cyclin‐dependent kinases 1 or 2, which, as a complex,
regulates the cell cycle. The complex phosphorylates serine or threonine
in the S phase during DNA replication as well as in the transition from
the G2 phase to mitosis. Cyclin‐dependent kinases inhibitors have been
investigated for anticancer therapy. The first approved cyclin‐depen-
dent kinases4/6 inhibitor was palbociclib in metastatic breast cancer.1,2
Ki67, the clinically most commonly used proliferation marker, is a cell
cycle regulator present throughout all the active phases of division,
indicating the proportion of proliferative cells.
Desmoid tumors are infiltrative mesenchymal tumors with an
unpredictable clinical behavior. Active surveillance is the strategy for
patients with nonprogressive and symptomless tumors. Other
management options include surgery, radiotherapy, and/or medical
therapy.3 Approximately 95% of sporadic desmoids carry a mutation
in the β‐catenin CTNNB1 or the APC gene.4 Patients with familial
adenomatous polyposis (FAP) harbor a germline APC mutation that
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predisposes to the development of desmoid tumors.5,6 Several risk
factors for recurrence after surgery have been described. A recent
literature survey indicated that young age and positive surgical
margins are prognostic for recurrence in multivariate analysis. Tumor
size was prognostic in 2 of the 4 studies testing size in multivariate
analysis.7 In a meta‐analysis of 1295 patients with surgically treated
extra‐abdominal desmoid tumors, a positive resection margin was
associated with a higher recurrence rate. Adjuvant radiotherapy after
surgery with positive margins decreased the recurrence rate.8
Another multivariate analysis of 495 patients also identified
extremity location but not surgical margin as a prognostic factor
for recurrence.9
High Ki67 and cyclin A are associated with a poor prognosis in
breast cancer, prostate carcinomas, and soft‐tissue sarcomas.10-12
However, the role of proliferation in desmoid tumors has not been
clearly defined. Ki67 expression in desmoid tumors has been
assessed using various techniques and cut‐off points, with incon-
sistent results. To our knowledge, cyclin A expression has not been
evaluated in desmoid tumors. This work aims to assess the prognostic
value and association of Ki67 and cyclin A by immunohistochemistry
with clinicopathological parameters in desmoid tumors.
2 | MATERIAL AND METHODS
2.1 | Patients
The study included 90 patients with desmoid tumors referred to
Helsinki University Hospital between 1987 and 2011. Clinical data
were retrieved from patient charts and databases. An experienced
sarcoma pathologist (MR) re‐evaluated the diagnostic specimens.
Patients lacking clinical data or follow‐up were excluded, as was one
patient with an incorrect diagnosis on review. The study was
approved by the Ethics Committee of Helsinki University Hospital
(270/13/03/00/2011) and the National Supervisory Authority for
Welfare and Health. The study was conducted in accordance with the
Helsinki Declaration.
2.2 | Tissue arrays and immunohistochemistry
The tissue micro array (TMA) was generated from formalin‐fixed
paraffin‐embedded surgical specimens. The pathologist (MR) selected
the representative tumor areas for punching, and 3 or more 1mm
punches were obtained from each tumor. Punching was carried out
using a manual microarrayer (BeecherInstruments Inc, Silver Spring,
MD). Three parallel tissue array blocks were created.
Tissue array blocks were cut into 4 μm thick sections and
subsequently deparaffinized with xylene and rehydrated with graded
concentrations of ethanol. Antigen retrieval was performed in Tris‐
EDTA buffer (pH 9) in the pretreatment module by heating sections.
Immunostainings were carried out with mouse monoclonal cyclin A
antibody (NCL‐Cyclin A; Novocastra, Newcastle, UK, dilution 1:50)
and anti‐Ki67 (anti‐human Ki67 Antigen Clone MIB‐1; Novocastra,
dilution 1:100). Pretreatment and staining were performed with
Autostainer 480® (LabVision, Fremont, CA) using the Dako REAL
EnVision Detection System®, peroxidase/DAB+, Rabbit/Mouse
(Glostrup, Denmark). Tissues were incubated for 60min with the
primary antibodies and for 30min with HRP. Counterstaining was
performed with hematoxylin and DAB+ and mounted in mounting
medium (Pertex®, Histolab, Sweden). Tissue specimens from human
colon, stomach, and pancreas served as controls.
2.3 | Immunostainings
The TMA slides were digitalized using the Pannoramic 250® digital
scanner (3DHistech, Budapest, Hungary). KS performed the digital
image analysis with Pannoramic Viewer® and NuclearQuant®
software (3DHistech) for each tumor core blinded from the clinical
data. Ki67 and cyclin A expressions were calculated as continuous
percentages of immunopositive tumor cell nuclei within the
annotated tumor areas. Digitally obtained data were reviewed before
inclusion. All specimens with ≥300 neoplastic nuclei were included
for analysis. If more than one specimen was acceptable per patient,
the one with the highest proliferation rate was chosen out of core
biopsies with >500 tumor cells. In cores with 300‐500 tumor cells,
the specimen with the highest tumor cell number was selected.
Nuclear β‐catenin was immunohistochemically examined and found
to be expressed in all tumors.
2.4 | Statistical analysis
The SPSS 24® software for Windows (SPSS, Chicago, IL) was used
for statistical analysis. The significance of associations between
cyclin A, Ki67, and clinicopathological characteristics was deter-
mined using Student t test or Pearson’s correlation test for
dichotomous and continuous variables, respectively. Recurrence‐
free survival (RFS) was calculated from the first operation with the
radical aim of detection of the first recurrence. Two patients with
incomplete follow‐up data were excluded from the RFS analysis,
one of these the only one with R2 resection. The association of
clinical and histological variables with RFS was analyzed in
univariate and multivariate Cox regression models. Due to the
low number of events, multivariate analyzes with only 1 or 2
factors in addition to cyclin A were performed. The log‐rank test
was used to compare RFS between high and low cyclin A
expression, and the results were visualized as a Kaplan‐Meier
curve. A 2‐tailed P‐value of .05 was considered significant.
Determination of optimal cyclin A and Ki67 cut‐off values was
done by partitioning the patient material at 10% steps from the
10th to the 90th percentile and calculating the hazard ratio,
confidence intervals, and P‐value at each step.
3 | RESULTS
Cyclin A and Ki67 were assessable in 74 and 70 of 90 patients,
respectively. Fourteen patients were not evaluable for cyclin A or
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Ki67 due to failed staining or low cell number, and were excluded.
The median follow‐up was 11 years (range from 0.1 to 29 years).
Patient and treatment characteristics are shown in Table 1.
3.1 | Expression of cyclin A and Ki67
Cyclin A immunopositivity varied from 0% to 9.9%, with a median
of 1.5% and a mean of 1.9%. Ki67 immunopositivity varied
from 0.3% to 13.8%, with a median of 3.9% and a mean of 4.6%
(Figure 1). Both cyclin A and Ki67 immunostainings were detected
only in tumor cell nuclei. Cyclin A significantly correlated with
Ki67 (rp = .79, P < .001).
3.2 | Associations between clinical characteristics
and immunohistochemical expression of cyclin A
and Ki67
Associations between cyclin A and clinical characteristics are listed in
Table 1. High cyclin A expression was associated significantly with
tumor size (rp = .28, P = .03) and sex (P = .04). There was no
correlation between cyclin A expression and patient age, tumor
location, resection margin, FAP, pregnancy associated tumor, or
postoperative radiotherapy. Ki67 overexpression correlated signifi-
cantly with age (rp = −.26, P = .03), tumor size (rp = .32, P = .01),
pregnancy‐associated tumor (P = .04), and FAP (P = .001). There was
194 | SANTTI ET AL.
TABLE 1 Clinical characteristics of 76 patients with surgically treated desmoid tumors and the association of 74 patients’ characteristics and
cyclin A expressiona
All Cyclin A lowb Cyclin A high
n (%) 76 (100) 60 (81)a 14 (19) P‐value
Mean age at diagnosis ± SD 39 ± 14 41 ± 14 33 ± 13 .2
Sex
Female 53 (70) 43 (72) 8 (57) .04
Male 23 (30) 17 (28) 6 (43)
Pregnancy‐associated desmoid
Yes 11 (15) 9 (15) 1 (7) .1
No 65 (85) 51 (85) 13 (93)
FAP
Yes 9 (12) 5 (8) 4 (19) .1
No 67 (88) 55 (92) 10 (81)
Mean size of the primary tumor ± SD, cmc 8 ± 7 7 ± 4 12 ± 11 .03
Location .8d
Extremities 15 (20) 13 (21) 2 (15)
Head and neck 4 (5) 3 (5) 1 (7)
Trunk 50 (66) 40 (67) 8 (57)
Intra‐abdominal 6 (8) 4 (7) 2 (14)
Multifocal 1 (1) 0 (10) 1 (7)
Surgery and marginse 1.0
R0 35 (46) 28 (47) 5 (36)
R1 23 (31) 17 (28) 6 (43)
R2 1 (1) 1 (2) 0
Adjuvant radiotherapy after the primary operation
Yes 7 (9) 6 (10) 1 (7) .5
No 69 (91) 54 (90) 13 (93)
aCyclin A was evaluable in 74 patients.
bThe cut‐point between low and high cyclin A expression was 2.98%.
cThe size of 12 tumors could not be obtained.
d0 = other, 1 = extremities.
eThe margins were not recorded in 17 tumors. Statistical testing was performed comparing negative (R0) with positive (R1 and R2) resection margins.
The T‐test was used for dichotomous variables and Pearson’s test was used for continuous variables. FAP, familial adenomatous polyposis; SD, standard
deviation.
no correlation between Ki67 expression and sex, tumor localization,
resection margin, or postoperative radiotherapy.
3.3 | Prognosis
Cox univariate analysis showed that positive surgical margin (HR
5.2, 95% CI = 1.6‐16.2, P = .005), extremity location (HR 5.0, 95%
CI = 2.0‐12.5, P = .001), high cyclin A expression (HR = 1.3, 95%
CI = 1.0‐1.5, P = .02), and sex (HR 2.6, 95% CI = 1.1‐6.2, P = .03) were
associated with RFS (Table 2). Ki67 had no significant prognostic
impact. In multivariate analysis, extremity location (HR 5.3, 95%
CI = 1.7‐16.8, P = .005), positive surgical margin (HR 6.0, 95%
CI = 1.6‐22.5, P = .008), and high cyclin A expression (HR 1.9, 95%
CI = 1.1‐3.2, P = .02) were independent prognostic variables
(Table 2). Multivariate analyzes including only two factors retained
the significance for cyclin A in models including either surgical
margin (P = .005) or location (P = .01).
All 9 alternative cut‐offs indicated a higher risk of progression with
high cyclin A values; however, the cut‐offs at the 70‐90 percentiles
SANTTI ET AL. | 195
F IGURE 1 Immunostainings of cyclin A and Ki67 expression in desmoid tumor tissue: (A) low cyclin A ≤ 2.98%, (B) high cyclin A > 2.98%,
(C) low Ki67 ≤ 5.99%, (D) high Ki67 < 5.99% [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 2 Cox univariate and multivariate analysis of recurrence‐free survival
Univariate Multivariate
HR (95% CI) P‐value HR (95% CI) P‐value
Positive surgical margina 5.2 (1.6‐16.2) .005 6.0 (1.6‐22.5) .008
Extremity locationb 5.0 (2.0‐12.5) .001 5.3 (1.7‐16.8) .005
Cyclin A 1.3 (1.0‐1.5) .02 1.9 (1.1‐3.2) .02
Ki67 1.1 (0.95‐1.2) .2
Sexc 2.6 (1.1‐6.2) .03
Age 1.0 (1.0‐1.0) .6
Tumor size 1.0 (0.9‐1.1) .9
Postoperative radiotherapyd 1.2 (0.3‐5.0) .8
a0 = positive, 1 = negative.
b0 = other, 1 = extremities.
c0 = female, 1 = male.
d0 = no, 1 = yes.
yielded the most consistent and significant association with prognosis
(Table 3). The lowest cut‐off at 0.72% displayed a very high hazard
rate for progression, but the confidence levels were extremely wide
due to only one recurrence in the low proliferation group. RFS
according to cyclin A levels at the 80% percentile cut‐off at 2.98%
showed a hazard rate of 3.5 (P = .006) and is shown in Figure 2. None
of the nine alternative cut‐off values for Ki67 yielded any significant
association with RFS. HR varied between 0.9 and 2.3, with the highest
HR (2.3) at the 70th percentile (5.99%), with a P‐value of .07
(Supporting Information Table 1).
4 | DISCUSSION
In the present study, high cyclin A was significantly associated
with postoperative RFS in desmoid tumors, whereas Ki67 showed
only a nonsignificant trend toward being prognostic. Proliferation
biomarkers have not previously been extensively studied
in desmoid tumors. To our knowledge, cyclin A expression
has not been investigated before in desmoid tumors, whereas
only a few studies have investigated the prognostic impact
of Ki67, with conflicting results. Ki67 is an established prognostic
and predictive tool in various cancer types, such as breast
cancer, soft‐tissue sarcomas, and neuroendocrine neoplasms,
and it is probably the most extensively studied proliferation
marker.13-15
Expression of Ki67 and cyclin A was low compared with
malignant mesenchymal tumors. The median Ki67 index was 3.9%
(mean 4.6%) and the median percentage of cyclin A positive nuclei
was 1.5% (mean 1.9%). In a previous study of sarcomas by our
group, the corresponding values were 18% and 11%, respec-
tively.11,16 In another series of 193 patients with soft‐tissue
sarcomas of the trunk and extremities, the median Ki67 index was
30%.17 Furthermore, in 216 patients with nonvisceral soft‐tissue
sarcoma, the median Ki67 index was 12%.18 In desmoid tumors,
previously published data on Ki67 expression agree with the
present study in that proliferation is low, with mean Ki67 rates
ranging from unmeasurable to 8.7%.19-24 Visual analysis in four
studies with 38, 15, 31, and 51 patients yielded mean Ki67
proportions of 3.0%, 3.2%, 8.7%, and 1.9%, respectively.21-23,25
Digital Ki67 scoring in a study of 42 patients with desmoid tumors
yielded a mean rate of 6%,24 whereas another study of 80 patients
reported a mean value of 8.1%, with the highest scores in extra‐
abdominal tumors.20 In some publications without explicit numer-
ical values, Ki67 was stated to be positive from 3% to 38% of
tumors, with various cut‐off values from 2% to 5%,26-28 whereas
others only briefly mentioned that proliferation was low.29,30
Three previous studies have evaluated Ki67 as a prognostic
biomarker in desmoid tumors.23,31,32 One of these, however,
studied a mixture of sarcomas and desmoid tumors and separate
results from desmoid tumors were not reported.31 One of the
remaining studies with 33 patients with desmoid tumors reported
an association with high Ki67 and short disease‐free survival,
whereas Ki67 was not prognostic in the other study (n = 51).23,32
Despite the fact that Ki67 and cyclin A were significantly
correlated in the present study, high Ki67 labeling was
only weakly and non‐significantly prognostic in contrast to
cyclin A.
Overexpression of cyclin A has been reported to be an
unfavorable prognostic indicator in soft‐tissue sarcomas and in
breast cancer, but has not, to our knowledge, been reported
in desmoid tumors.10,11,33 Cyclin A regulates the cell cycle progres-
sion in S and G2 phases, whereas Ki67 is present in all the cell cycle
phases besides the resting phase G0. Hypothetically, the more
restricted expression of cyclin A in cells committed to cell division
may explain the superior accuracy of cyclin A in comparison with
Ki67. In agreement with our findings in desmoid tumors, previous
studies suggest a superior prognostic value for cyclin A also in soft‐
tissue sarcomas and colorectal cancer.11,33
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TABLE 3 Cox univariate analysis of cyclin A expression divided
from 10th to 90th percentiles and recurrence‐free survival
Cut‐off % Cut‐off value HR (95% CI) P‐value
10 0.72 24.3 (0.1‐9958.1) .3
20 0.91 1.4 (0.4‐4.9) .6
30 1.08 2.0 (0.7‐5.9) .2
40 1.37 1.4 (0.6‐3.5) .5
50 1.54 1.6 (0.7‐3.9) .3
60 1.76 1.6 (0.7‐4.0) .3
70 2.42 2.8 (0.2‐6.8) .02
80 2.98 3.5 (1.4‐8.6) .006
90 3.55 2.8 (0.9‐8.4) .07
F IGURE 2 Recurrence‐free survival in 72 patients with operated
desmoid tumors according to cyclin A expression with a 2.98%
cut‐point
The TMA technique enables an efficient immunohistochemical
evaluation of large tumor materials, albeit TMA cores may yield
different scores than whole sections due to intratumoral varia-
tions, which may be a limitation of the present study. However,
TMA has been validated for fibroblastic neoplasms, including
desmoid tumors, with a Ki67 concordance of 96% between whole
sections and triplicate TMA cores.31 The relatively homogenic
tissue of desmoid tumors probably makes it especially suitable
for TMA. The major strengths of this study include histologically
re‐evaluated and confirmed diagnosis of all cases, objective
proliferation scoring by quantitative image analysis, and a long
follow‐up duration.
5 | CONCLUSIONS
Cyclin A overexpression is an independent prognostic factor of
relapse in desmoid tumors after resection.
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